KLRS Kalaris Therapeutics, Inc. - Common Stock
$4.10
Price · Aug 19, 2026
Fundamentals as of Aug 11, 2026
52W Range
$2–$12
19% of range
Analyst Rating
STRONG BUY
14 analysts
Price Target
$19
+356% upside
P/E (TTM)
-1.4
ROE
-65.8%
Net Profit Margin
—
KLRS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$4.10
Market Cap
$94M
P/E (TTM)
-1.4
EPS (TTM)
$-2.85
Revenue (TTM)
—
Div Yield
—
ROE
-65.8%
Debt/Equity
—
52W Range
$2 – $12
KLRS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
2019-12-31
→
2019-12-31
EPS
$-2.85
2021-12-31
→
2025-12-31
Free Cash Flow
$-39M
2020-12-31
→
2025-12-31
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
KLRS
Peer Median
P/E (TTM)
-1.4
2.6
P/B
1.2
3.1
Price / FCF
-2.4
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
KLRS
Peer Median
ROA
-67.9%
-60.9%
ROE
-65.8%
-99.5%
ROIC
-58.6%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
KLRS
Peer Median
Current Ratio
12.2
2.6
Quick Ratio
12.1
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
KLRS
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
KLRS
Peer Median
KLRS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
14 analysts
- Strong Buy 6 42.9%
- Buy 6 42.9%
- Hold 2 14.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
7 analysts · 2026-08-19
Median
$20.00
← Below all targets
$4.10
Low
$7.00
High
$25.00
Median target
$20.00
+387.8%
Mean target
$18.71
+356.4%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.06%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.46 | $-0.53 | 0.07% |
| Dec. 31, 2025 | $-0.51 | $-0.54 | 0.03% |
| Sept. 30, 2025 | $-0.64 | $-0.67 | 0.03% |
| June 30, 2025 | $-0.61 | $-0.53 | -0.08% |
| March 31, 2025 | $-2.52 | $-0.79 | -1.7% |
| June 30, 2024 | $-1.15 | $-2.46 | 1.3% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| KLRS | $193M | -3.0 | — | — | -65.8% | — |
| FBIO | — | — | — | — | — | — |
| GANX | $135M | -5.3 | -60.6% | — | -181.1% | — |
| RLYB | $4M | -0.4 | 34.9% | -1046.4% | -17.3% | — |
| ICCC | — | -51.2 | 4.3% | — | — | — |
| ACRV | $76M | -1.2 | — | — | -61.0% | — |
| ATRA | $132M | 7.0 | -6.3% | 27.1% | -88.9% | — |
| ACET | — | -0.5 | — | — | — | — |
| SERA | — | -4.4 | 5.2% | -39417.3% | -39.0% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 16
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $165.0K | |
| R&D Expense | $31M | $45M | $133M | $119M | $121M | $50M | $16M | |
| SG&A Expense | $15M | $7M | $48M | $52M | $49M | $22M | $11M | |
| Operating Expenses | $46M | $52M | $200M | $171M | $170M | $71M | $27M | |
| Operating Income | $-46M | $-52M | $-200M | $-171M | $-170M | $-71M | $-27M | |
| Interest Expense | $1M | $3M | · | · | · | · | · | |
| Interest Income | · | $5M | $6M | $2M | $1M | $1M | $2M | |
| Other Non-op | $3M | $188.0K | $4M | $351.0K | $-2M | $195.0K | $797.0K | |
| Pretax Income | $-43M | $-69M | $-191M | $-169M | $-171M | $-70M | $-24M | |
| Income Tax | $0 | $0 | $-126.0K | $-265.0K | $1M | · | · | |
| Net Income | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | $-24M | |
| EPS (Basic) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| EPS (Diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| Shares (Basic) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| Shares (Diluted) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| EBITDA | $-46M | $-65M | $-200M | $-170M | · | $-71M | · |
Balance Sheet 21
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $98M | $2M | $90M | $106M | $202M | $123M | $61M | |
| Short-term Investments | $20M | $0 | $94M | $128M | $46M | $234M | $65M | |
| Prepaid Expense | $827.0K | $967.0K | $3M | $7M | $5M | $5M | $676.0K | |
| Current Assets | $119M | $3M | $188M | $243M | $253M | $361M | $127M | |
| PP&E (Net) | · | · | · | $930.0K | $2M | $812.0K | $350.0K | |
| PP&E (Gross) | · | · | $2M | $2M | $2M | $904.0K | $369.0K | |
| Accum. Depreciation | · | · | · | $1M | $281.0K | $92.0K | $19.0K | |
| Other Non-current Assets | $953.0K | $410.0K | $122.0K | $612.0K | $1M | · | · | |
| Total Assets | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Accounts Payable | $1M | $2M | $7M | $3M | $8M | $963.0K | $630.0K | |
| Accrued Liabilities | · | $5M | $10M | $14M | $20M | $8M | $5M | |
| Current Liabilities | $10M | $25M | $28M | $24M | $38M | $12M | $9M | |
| Capital Leases | $1M | $0 | $17M | $28M | $23M | $5M | $9M | |
| Total Liabilities | $43M | $57M | $45M | $53M | $61M | $18M | $18M | |
| Common Stock | $2.0K | $0 | $0 | $9.0K | $7.0K | $7.0K | · | |
| Paid-in Capital | $239M | $20M | $802M | $691M | $522M | $478M | $4M | |
| Retained Earnings | $-160M | $-117M | $-656M | $-466M | $-297M | $-125M | $-55M | |
| AOCI | $6.0K | $0 | $-62.0K | $-468.0K | $-155.0K | $-112.0K | $68.0K | |
| Stockholders' Equity | $79M | $-97M | $-45M | $225M | $225M | $353M | $-52M | |
| Liabilities + Equity | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Shares Outstanding | 22,902,418 | 1,356,431 | 4,962,997 | 93,093,243 | 63,565,886 | 61,931,255 | 2,099,740 |
Cash Flow 15
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $398.0K | $723.0K | $189.0K | $73.0K | $19.0K | |
| Stock-based Comp | $2M | $895.0K | $41M | $41M | $44M | $9M | $3M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $10M | · | · | · | · | · | |
| Other Non-cash | · | · | $25M | $-15M | · | $-529.0K | · | |
| Operating Cash Flow | $-38M | $-21M | $-124M | $-142M | $-106M | $-61M | $-20M | |
| CapEx | $200.0K | · | · | · | $26.0K | $235.0K | $339.0K | |
| Investing Cash Flow | $-20M | $95M | $38M | $-80M | $186M | $-169M | $-65M | |
| Stock Issued | $42M | · | · | $126M | · | · | · | |
| Net Stock Activity | $42M | · | · | $126M | · | · | · | |
| Financing Cash Flow | $155M | $19M | $70M | $127M | $232.0K | $292M | $121M | |
| Net Change in Cash | $97M | $-2M | $-16M | $-96M | $80M | $62M | $36M | |
| Taxes Paid | $0 | $0 | $220.0K | $613.0K | · | · | · | |
| Free Cash Flow | $-39M | · | · | · | · | $-61M | · | |
| Levered FCF | $-40M | · | · | · | · | · | · |
Profitability 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ROA | -67.9% | -38.0% | -81.4% | -59.9% | · | -27.4% | · | |
| ROE | -65.8% | -491.2% | -111.6% | -70.6% | · | -19.2% | · | |
| ROIC | -58.6% | -57.8% | -137.0% | -76.1% | · | · | · |
Liquidity & Solvency 3
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.2 | 22.6 | 6.6 | 10.0 | · | 29.4 | · | |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · | 29.0 | · | |
| Interest Coverage | -32.0 | · | · | · | · | · | · |
Valuation (TTM) 8
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | · | |
| Market Cap | $193M | $49M | $1.79B | $10.98B | · | $54.75B | · | |
| P/E | -3.0 | -0.2 | -0.4 | -53.6 | -108.6 | · | · | |
| P/B | 2.5 | 0.4 | 12.2 | 48.9 | · | 155.1 | · | |
| P / Tangible Book | 2.5 | · | · | 48.9 | 84.0 | 155.1 | · | |
| P / Cash Flow | -5.0 | -0.7 | -14.3 | -77.3 | · | -900.4 | · | |
| P / FCF | -5.0 | · | · | · | · | -896.9 | · | |
| Earnings Yield | -33.8% | -535.9% | -269.1% | -1.9% | -0.92% | · | · |
Income Statement 15
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $9M | $8M | $7M | $9M | $8M | $6M | $4M | $36M | $3M | $2M | $33M | $34M | $35M | $31M | $28M | $30M | |
| SG&A Expense | $3M | $4M | $4M | $4M | $4M | $4M | $3M | $2M | $976.0K | $602.0K | $10M | $13M | $12M | $13M | $12M | $13M | |
| Operating Expenses | $12M | $12M | $11M | $13M | $12M | $10M | $7M | $38M | $4M | $3M | $62M | $47M | $47M | $43M | $40M | $43M | |
| Operating Income | $-12M | $-12M | $-11M | $-13M | $-12M | $-10M | $-7M | $-38M | $-4M | $-3M | $-62M | $-47M | $-47M | $-43M | $-40M | $-43M | |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1M | $1M | $815.0K | $499.0K | $78.0K | · | · | · | · | · | · | |
| Interest Income | · | · | · | · | · | · | · | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $898.0K | $668.0K | |
| Other Non-op | $871.0K | $977.0K | $803.0K | $847.0K | $906.0K | $193.0K | $64.0K | $31.0K | $66.0K | $27.0K | $1M | $1M | $521.0K | $723.0K | $986.0K | $210.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | $-60M | $-44M | $-45M | · | $-39M | $-42M | |
| Income Tax | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-126.0K | $0 | $0 | $0 | $-415.0K | $0 | |
| Net Income | $-12M | $-11M | $-10M | $-12M | $-11M | $-10M | $-22M | $-38M | $-6M | $-3M | $-60M | $-44M | $-45M | $-41M | $-38M | $-42M | |
| EPS (Basic) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| EPS (Diluted) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| Shares (Basic) | 23,797,306 | 23,723,618 | -26,188,317 | 18,701,708 | 18,701,286 | 4,053,140 | -2,654,598 | 1,352,265 | 1,325,706 | 1,312,552 | -297,299,471 | 113,894,188 | 94,625,837 | 93,303,672 | -136,754,517 | 84,948,837 | |
| Shares (Diluted) | 23,797,306 | 23,723,618 | -26,188,317 | 18,701,708 | 18,701,286 | 4,053,140 | -2,654,598 | 1,352,265 | 1,325,706 | 1,312,552 | -297,299,471 | 113,894,188 | 94,625,837 | 93,303,672 | -136,754,517 | 84,948,837 | |
| EBITDA | $-12M | $-12M | · | $-13M | $-12M | $-10M | · | $-6M | $-8M | $-32M | · | $-47M | $-47M | $-43M | · | $-43M |
Balance Sheet 20
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $34M | $98M | $42M | $88M | $101M | $2M | $117M | $105M | $86M | $90M | $96M | $197M | $116M | $106M | $124M | |
| Short-term Investments | $50M | $63M | $20M | $35M | · | · | $0 | $5M | $25M | $54M | $94M | $118M | $50M | $87M | $128M | $140M | |
| Prepaid Expense | $2M | $861.0K | $827.0K | $1M | $3M | $1M | $967.0K | $626.0K | $230.0K | $771.0K | $3M | $6M | $5M | $7M | $7M | $6M | |
| Current Assets | $96M | $98M | $119M | $78M | $92M | $102M | $3M | $123M | $130M | $141M | $188M | $220M | $253M | $212M | $243M | $272M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $673.0K | $759.0K | $844.0K | $930.0K | $943.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Other Non-current Assets | $2M | $2M | $953.0K | $976.0K | $691.0K | $410.0K | $410.0K | · | · | · | $122.0K | $1M | $684.0K | $490.0K | $612.0K | $734.0K | |
| Total Assets | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Accounts Payable | $1M | $905.0K | $1M | $494.0K | $4M | $2M | $2M | $51.0K | $110.0K | $765.0K | $7M | $4M | $5M | $4M | $3M | $5M | |
| Accrued Liabilities | · | · | · | · | · | · | · | $1M | $2M | $5M | $10M | $16M | $17M | $12M | $14M | $14M | |
| Current Liabilities | $9M | $8M | $10M | $6M | $8M | $7M | $25M | $1M | $2M | $8M | $28M | $33M | $31M | $25M | $24M | $21M | |
| Capital Leases | $1M | $1M | $1M | $1M | · | · | $0 | · | $8M | $16M | $17M | $20M | $23M | $26M | $28M | $20M | |
| Total Liabilities | $42M | $41M | $43M | $39M | $40M | $39M | $57M | $1M | $11M | $24M | $45M | $53M | $54M | $51M | $53M | $40M | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $11.0K | $11.0K | $11.0K | $0 | $11.0K | $11.0K | $9.0K | $9.0K | $9.0K | |
| Paid-in Capital | $240M | $239M | $239M | $192M | $191M | $191M | $20M | $818M | $813M | $807M | $802M | $792M | $782M | $701M | $691M | $681M | |
| Retained Earnings | $-182M | $-171M | $-160M | $-150M | $-138M | $-127M | $-117M | $-697M | $-693M | $-686M | $-656M | $-596M | $-552M | $-507M | $-466M | $-428M | |
| AOCI | $-73.0K | $-49.0K | $6.0K | $6.0K | · | · | $0 | $-134.0K | $-139.0K | $-138.0K | $-62.0K | $-200.0K | $-225.0K | $-301.0K | $-468.0K | $-563.0K | |
| Stockholders' Equity | $58M | $69M | $79M | $42M | $53M | $64M | $-97M | $121M | $120M | $120M | $146M | $195M | $229M | $194M | $225M | $253M | |
| Liabilities + Equity | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Shares Outstanding | 23,804,981 | 22,992,291 | 22,902,418 | 18,702,418 | 18,702,418 | 18,702,418 | 1,356,431 | 115,438,119 | 115,312,411 | 114,881,765 | 4,962,997 | 113,966,594 | 113,716,018 | 93,427,990 | 93,093,243 | 92,640,109 |
Cash Flow 12
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | $141.0K | $86.0K | $85.0K | $86.0K | $86.0K | $85.0K | |
| Stock-based Comp | $644.0K | $580.0K | $333.0K | $638.0K | $591.0K | $374.0K | $280.0K | $-10M | $-5M | $31.0K | $10M | $10M | $10M | $10M | $9M | $11M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Restructuring | · | · | · | · | · | · | · | $100.0K | $500.0K | $10M | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | · | $-1M | · | · | |
| Operating Cash Flow | $-11M | $-12M | $-7M | $-11M | $-13M | $-7M | $-8M | $43M | $36M | $-5M | $-31M | $-34M | $-27M | $-32M | $-32M | $-35M | |
| CapEx | · | · | $17.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $20M | $-50M | $15M | · | · | · | · | $20M | $30M | $40M | $25M | $-67M | $38M | $42M | $14M | $-39M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Financing Cash Flow | $-377.0K | $-2M | $48M | $0 | $0 | $107M | $8M | $12M | $5M | $7M | $11.0K | $0 | · | · | $292.0K | $126M | |
| Net Change in Cash | $9M | $-64M | $56M | $-46M | $-13M | $100M | $-274.0K | $-16M | $7M | $2M | $-6M | $-101M | $81M | $10M | $-18M | $53M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $-131.0K | $1.0K | · | · | $-390.0K | $0 |
Profitability 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -12.0% | -10.2% | · | -11.7% | -10.1% | -8.2% | · | -2.2% | -2.9% | -15.6% | · | -16.3% | -18.8% | -17.3% | · | -13.8% | |
| ROE | -20.8% | -16.4% | · | -14.6% | -13.1% | -11.1% | · | -2.6% | -3.5% | -19.3% | · | -19.7% | -23.4% | -21.4% | · | -16.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -24.0% | -20.6% | · | · | · |
Liquidity & Solvency 3
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 12.2 | · | 12.9 | 12.0 | 14.3 | · | 86.8 | 55.1 | 18.5 | · | 6.7 | 8.3 | 8.5 | · | 13.1 | |
| Quick Ratio | 10.7 | 12.0 | · | 12.7 | 11.6 | 14.1 | · | 86.3 | 54.9 | 18.4 | · | 6.5 | 8.1 | 8.1 | · | 12.7 | |
| Interest Coverage | · | · | · | · | · | -7.2 | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM) 7
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-46M | $-44M | · | $-72M | $-65M | $-57M | · | $-91M | $-99M | $-134M | · | $-173M | $-173M | $-172M | · | $-176M | |
| Market Cap | $97M | $133M | · | $108M | $50M | $150M | · | $2.15B | $1.92B | $1.99B | · | $5.64B | $8.89B | $8.47B | · | $16.81B | |
| P/E | -1.9 | -1.4 | · | -0.2 | -0.1 | -0.2 | · | -0.5 | -2.2 | -4.4 | · | -27.3 | -37.1 | -39.1 | · | -69.8 | |
| P/B | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Tangible Book | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Cash Flow | · | -11.5 | · | · | · | -20.2 | · | · | · | -45.0 | · | · | · | -263.6 | · | · | |
| Earnings Yield | -53.8% | -73.3% | · | -552.4% | -1331.5% | -467.5% | · | -190.3% | -46.5% | -22.5% | · | -3.7% | -2.7% | -2.6% | · | -1.4% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Net Income | $-43M | $-69M | $-190M | $-169M | $-172M |
| Diluted EPS | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Current Ratio | 12.2 | 22.6 | 6.6 | 10.0 | — |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | — |
Cash Flow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Free Cash Flow | $-39M | — | — | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 58 filers · $74.1M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 13 (+1 vs prior Q) | 11 (+4 vs prior Q) | 15 (0 vs prior Q) | 9 (+1 vs prior Q) | -333K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | $52,426,382 | 12,881,175 | 70.79% | Shares |
| RTW INVESTMENTS, LP | $5,291,000 | 1,300,000 | 7.14% | Shares |
| Alyeska Investment Group, L.P. | $2,330,836 | 572,687 | 3.15% | Shares |
| VANGUARD GROUP INC | $2,155,137 | 255,348 | 2.91% | Shares |
| Siren, L.L.C. | $1,773,698 | 435,798 | 2.40% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $1,622,758 | 398,712 | 2.19% | Shares |
| Ikarian Capital, LLC | $1,465,201 | 360,000 | 1.98% | Shares |
| UBS Group AG | $1,066,873 | 262,131 | 1.44% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $607,859 | 149,351 | 0.82% | Shares |
| Woodline Partners LP | $407,000 | 100,000 | 0.55% | Shares |
| ADAR1 Capital Management, LLC | $407,000 | 100,000 | 0.55% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $404,332 | 99,306 | 0.55% | Shares |
| WHI TRUST Co LLC | $396,797 | 97,493 | 0.54% | Shares |
| CITADEL ADVISORS LLC | $389,792 | 95,772 | 0.53% | Shares |
| BOOTHBAY FUND MANAGEMENT, LLC | $375,502 | 92,261 | 0.51% | Shares |
| Verdad Advisers, LP | $326,809 | 80,297 | 0.44% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $269,349 | 66,179 | 0.36% | Shares |
| Fortis Capital Advisors, LLC | $162,800 | 40,000 | 0.22% | Shares |
| Belpointe Asset Management LLC | $162,800 | 40,000 | 0.22% | Shares |
| Pale Fire Capital SE | $161,278 | 39,626 | 0.22% | Shares |
| Squarepoint Ops LLC | $157,814 | 38,775 | 0.21% | Shares |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $132,275 | 32,500 | 0.18% | Shares |
| Stonepine Capital Management, LLC | $122,597 | 30,122 | 0.17% | Shares |
| Connor, Clark & Lunn Investment Management Ltd. | $122,128 | 30,007 | 0.16% | Shares |
| Trexquant Investment LP | $121,030 | 29,737 | 0.16% | Shares |
| STATE STREET CORP | $107,896 | 26,510 | 0.15% | Shares |
| NORTHERN TRUST CORP | $105,165 | 25,839 | 0.14% | Shares |
| Velan Capital Investment Management LP | $101,750 | 25,000 | 0.14% | Shares |
| TWO SIGMA INVESTMENTS, LP | $97,057 | 23,847 | 0.13% | Shares |
| WealthTrust Asset Management, LLC | $83,093 | 20,416 | 0.11% | Shares |
| Independent Advisor Alliance | $73,769 | 18,125 | 0.10% | Shares |
| RBF Capital, LLC | $70,781 | 17,391 | 0.10% | Shares |
| MORGAN STANLEY | $69,642 | 17,111 | 0.09% | Shares |
| Quadrature Capital Ltd | $67,265 | 16,527 | 0.09% | Shares |
| GOLDMAN SACHS GROUP INC | $65,340 | 16,054 | 0.09% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57,879 | 14,221 | 0.08% | Shares |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $50,875 | 12,500 | 0.07% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $48,168 | 11,835 | 0.07% | Shares |
| MARSHALL WACE, LLP | $42,068 | 10,336 | 0.06% | Shares |
| Sigma Planning Corp | $41,380 | 10,167 | 0.06% | Shares |
| FMR LLC | $31,770 | 7,806 | 0.04% | Shares |
| RAYMOND JAMES FINANCIAL INC | $28,490 | 7,000 | 0.04% | Shares |
| Integrated Wealth Concepts LLC | $20,350 | 5,000 | 0.03% | Shares |
| Tower Research Capital LLC (TRC) | $10,419 | 2,560 | 0.01% | Shares |
| Steward Partners Investment Advisory, LLC | $9,015 | 2,215 | 0.01% | Shares |
| BlackRock, Inc. | $7,021 | 1,725 | 0.01% | Shares |
| Vanguard Global Advisers, LLC | $2,951 | 725 | 0.00% | Shares |
| BARCLAYS PLC | $1,233 | 303 | 0.00% | Shares |
| Strengthening Families & Communities, LLC | $1,091 | 268 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $212 | 52 | 0.00% | Shares |
| Parallel Advisors, LLC | $199 | 49 | 0.00% | Shares |
| JPMORGAN CHASE & CO | $194 | 46 | 0.00% | Shares |
| HRT FINANCIAL LP | $55 | 13,723 | 0.00% | Shares |
| HARBOUR INVESTMENTS, INC. | $53 | 13 | 0.00% | Shares |
| Virtu Financial LLC | $44 | 10,845 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $28 | 7 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $20 | 5 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 12 | 0.00% | Shares |
Company insiders 30 insiders · 13 officers · 20 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Andrew Oxtoby | President and Chief Executive Officer | March 19, 2026 A | — | 0 | 0 | $0 |
| Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | Feb. 21, 2025 S | 49,129 | 0 | 0 | $0 |
| Diana Brainard | Chief Executive Officer | Nov. 19, 2024 S | 723,363 | 0 | 0 | $0 |
| Liisa Ann Bayko | Chief Financial Officer | July 20, 2026 A | — | 0 | 0 | $0 |
| Matthew Gall | Chief Financial Officer | March 19, 2026 A | — | 0 | 0 | $0 |
| Matthew Feinsod | Chief Medical Officer | March 19, 2026 A | 4,030 | 0 | 0 | $0 |
| Brett R Hagen | Chief Accounting Officer | March 19, 2026 A | 0 | 0 | 1 | $-12,869 |
| Edward Miller | General Counsel | Feb. 21, 2025 S | 6,517 | 0 | 0 | $0 |
| Cintia Piccina | Chief Commercial Officer | July 3, 2023 A | 147,000 | 0 | 0 | $0 |
| Ann M. Leen | Chief Scientific Officer | Feb. 2, 2023 A | 124,006 | 0 | 0 | $0 |
| Jeroen B Van Beek | Chief Commercial Officer | Nov. 16, 2022 S | 333,726 | 0 | 0 | $0 |
| Ercem Atillasoy | This Form 4/A is being filed correct the transaction dates reported in the original Form 4 filed on October 24, 2022. Officer T | Oct. 21, 2022 S | 131,372 | 0 | 0 | $0 |
| Agustin Melian | Chief Medical Officer | Oct. 4, 2021 S | 453,529 | 0 | 0 | $0 |
| Laurie Keating | Director | Aug. 1, 2026 A | — | 0 | 0 | $0 |
| Napoleone Ferrara | Director | June 3, 2026 A | 504,000 | 0 | 0 | $0 |
| Michael Dybbs | Director | June 3, 2026 A | — | 0 | 0 | $0 |
| Morana Jovan-Embiricos | Director | June 3, 2026 A | 100,197 | 0 | 0 | $0 |
| David Hallal | Director | June 3, 2026 A | 2,143,662 | 0 | 0 | $0 |
| Anthony P Adamis | Director | June 3, 2026 A | — | 0 | 0 | $0 |
| Srinivas Akkaraju | Director | June 3, 2026 A | 11,444,503 | 0 | 0 | $0 |
| Leone D Patterson | Director | June 3, 2026 A | — | 0 | 0 | $0 |
| Samir Chandrakant Patel | Director | April 10, 2025 A | 100,800 | 0 | 0 | $0 |
| Derek N. Adams | Director | June 6, 2024 A | 70,000 | 0 | 0 | $0 |
| Malcolm Brenner | Director | June 6, 2024 A | 100,197 | 0 | 0 | $0 |
| Juan Vera | Director | June 6, 2024 A | 2,409,928 | 0 | 0 | $0 |
| Shawn Tomasello | Director | June 6, 2024 A | 70,000 | 0 | 0 | $0 |
| Jeffrey S Bornstein | Director | June 6, 2024 A | 110,197 | 0 | 0 | $0 |
| ElevateBio, LLC | Director | July 28, 2022 A | 16,674,766 | 0 | 0 | $0 |
| ANSBERT GADICKE | Director | July 28, 2022 A | 16,674,766 | 0 | 0 | $0 |
| John Robert Wilson | Director | May 25, 2021 A | 3,164,954 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC, Srinivas Akkaraju ×4 filings | May 22, 2026 | 54.20% | Amendment | — | SEC |
| ElevateBio, LLC (2) | Aug. 5, 2022 | — | Initial filing | — | SEC |
| F2 MG Ltd. (2), F2-TPO Investments, LLC (2), F2 MC, LLC (2), F2 Capital I 2020 LLC (2), F2 Bioscience AV 2022 LLC (2), Globeways Holdings Ltd. (2), Globeways Holdings II Ltd. (2), Morana Jovan-Embiricos (2) | Aug. 5, 2022 | — | Initial filing | — | SEC |
| ElevateBio LLC (2) | Aug. 13, 2020 | — | Initial filing | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.